Organ models · Drug discovery
Organoid Biofoundry
A publication about growing human tissue that behaves enough like an organ to answer a question. We cover the models, the assays built on them, and the reproducibility problems that decide whether any of it reaches a clinic.
Latest analysis
September 11, 2026 A ten-year lung organoid biobank bets on correlationA UT Health San Antonio observational study with NCI support has spent eight years building a living lung cancer organoid biobank paired with circulating tumor cells. It is unglamorous, underpowered per stratum, and possibly the most-cited kind of organoid work there is.
September 11, 2026
Can breast tumor organoids predict neoadjuvant response?
A single-center Chinese trial is correlating breast cancer organoid chemosensitivity with residual cancer burden, the histologic gold standard, and benchmarking organoids against MRI. The design is clean; the sample is not.
September 11, 2026
ORGANOTREAT puts chemogram-guided cancer care on trial
ORGANOTREAT is a three-study French program that randomizes advanced cancer patients between organoid chemogram-guided treatment and standard of care. Its design quietly concedes the field's biggest weaknesses and tries to engineer around them.
September 10, 2026
The fastest-mutating part of the donor genome is not on the organoid QC panel
A new catalog of tandem repeat variation across seven ape genomes and 69 long-read human and chimpanzee genomes shows these repeats mutate orders of magnitude faster than SNVs, are under strong constraint in coding sequence and 5 prime UTRs, and cluster in nervous-system and synaptic genes. No standard iPSC or organoid quality-control workflow measures them, which makes repeat length a hidden, donor-specific variable in every organoid drug screen.
September 10, 2026
206 patients in, and tumour-immune organoids still cannot choose your immunotherapy
A PROSPERO-registered systematic review pooled patient-derived tumour-immune organoids as predictors of checkpoint-inhibitor response across 23 studies and 206 patients. Sensitivity was 0.70, the apparent specificity of 0.97 rested on exactly one false positive, every study carried high risk of bias, and the authors conclude the assays should not yet decide whether immunotherapy is added.
September 10, 2026
Vascularized brain organoids, and the evidence a platform owes its users
Huang and Lin report a co-differentiation protocol that builds endothelial vasculature and microglia-like cells into brain organoids during formation, then apply the same platform to ultrasound-modeled traumatic brain injury and patient-derived glioblastoma. The developmental logic is sound and the molecular concordance is encouraging, but the paper contains no drug-response experiment, no functional activity data, and no reported sample sizes or statistics.
September 9, 2026
The ECM-exosome growth-plate axis is a testable spec, not a mechanism
A structured narrative review of 46 studies proposes an ECM-exosome axis in the growth plate as a framework for idiopathic short stature. Its own evidence tables show the central interface is untested, and its proposed decisive experiments are, almost verbatim, a requirements document for growth-plate organoids.
Start here
Standing explainers that do not go stale. Read the primer first if this field is new to you.
The primer
What is an organoid?
The biology behind the models: how a stem-cell-derived 3D tissue is grown, quality controlled, and read out, and where the resemblance to a real organ stops.
Model
Brain organoids
Self-organized cortical-like tissue: what develops, what does not, and why maturation is the binding constraint.
Model
Liver organoids
Metabolic and toxicological readouts, and how far they predict human hepatotoxicity.
Model
Kidney organoids
Nephron-like structures, off-target cell types, and what that means for injury models.
Constraint
The vascularization problem
Why organ models stop growing at a millimetre, and the approaches trying to get past it.
Sections
Section
Organ models
Each model reproduces some of an organ and omits the rest. These pages set out what is faithfully modelled, what is missing, and which questions the model can therefore be trusted to answer.
Section
Drug discovery
Patient-derived models, tumour screening, and high-throughput assays that have to survive a real pipeline.
Section
Analysis
Daily readings of new research, each asking what the work changes for this field.
How we work
We report what a model was validated against, not what it was advertised to do. Sample sizes, donor counts and passage numbers matter for reproducibility, so we quote them where the source does and note their absence where it does not. Preclinical results are reported as preclinical: an effect in a dish is not an effect in a patient, and we do not blur that line to make a headline. The full method, including how pieces are selected and produced, is on the about page.